MEDU-20. TARGETING OF MYC BY HDAC INHIBITION IN MYC AMPLIFIED GROUP 3 MEDULLOBLASTOMA

High-risk medulloblastoma (MB) remains a deadly disease with poor overall survival despite aggressive multi-modal treatment. Survivors suffer from important treatment-associated morbidity. Patients with Group 3 MB tumors with amplification or high expression of the transcription factor MYC have a pa...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Ecker, Jonas, Oehme, Ina, Selt, Florian, Kool, Marcel, Chavez, Lukas, Hohloch, Juliane, Valinciute, Gintvile, van Tilburg, Cornelis M., Schnölzer, Martina, Warnken, Uwe, Wechsler-Reya, Robert, Pfister, Stefan M., Witt, Olaf, Milde, Till
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475139/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.170
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak